Theradiag

Theradiag SA engages in the development, industrialization, and marketing of diagnosis kits in France and internationally. It offers auto-immunity products, such as FIDIS kits that allow detection of multiple analytes from the same sample in a single assay; immunofluorescence tests to screen and identify the auto-antibodies; ELISA tests for performing various tests simultaneously on the same plate; Chorus systems, a multi-parametric analyzer; and immunoblot tests, which allow simultaneous detection of antibodies. The company also provides genetic tests comprising AmplideX products line for the diagnosis of the Fragile X syndrome and associated disorders; xTAG Gastrointestinal Pathogens Panel kits for identifying various gastrointestinal pathogens; xTAG Respiratory Viral Panel kits for identification of common respiratory viruses; and BCR/ABL1 Quant tests that are in vitro diagnostic products. In addition, it offers a panel of reagents for identifying the type of infectious diseases; SQA-V system, a semen analyzer; and V-Sperm for loading results, pictures, and videos of the samples to the computer. Further, the company provides instrumentation, including Theralis that integrates multiplex FIDIS immunofluorescence and ELISA; Theralis µ, a solution for medium sized laboratories; CARIS, a solution to perform IFA, ELISA, and FIDIS multiplex assays; and Chorus, a multi-parameter analyser dedicated to auto-immunity and infectious disease. Theradiag SA was founded in 1986 and is based in Marne La Vallee, France.